首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site
【24h】

Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site

机译:喹啉 - 吲哚衍生物作为靶向血清素结合位点的抗微管蛋白剂的设计,合成和生物学评价

获取原文
获取原文并翻译 | 示例
           

摘要

A series of novel isocombretastatin A-4 (isoCA-4) analogs were designed and synthesized by replacing 3,4,5-trimethoylphenyl and isovanillin of isoCA-4 with quinoline and indole moieties, respectively. The structure activity relationships (SARs) of these synthesized quinoline-indole derivatives have been intensively investigated. Two compounds 27c and 34b exhibited the most potent activities against five cancer cell lines with IC50 values ranging from 2 to 11 nM, which were comparable to those of Combretastatin A-4 (CA-4, 1). Further mechanism investigations revealed that 34b effectively inhibited the microtubule polymerization by binding to the colchicine site of tubulin. Further cellular mechanism studies elucidated that 34b disrupted cell microtubule networks, arrested the cell cycle at G2/M phase, induced apoptosis and depolarized mitochondria of K562 cells. Moreover, 34b displayed potent anti vascular activity in both wound healing and tube formation assays. Importantly, 27c and 34b significantly inhibited tumor growth in H22 xenograft models without apparent toxicity, suggesting that 27c and 34b deserve further research as potent antitumor agents for cancer therapy. (C) 2018 Elsevier Masson SAS. All rights reserved.
机译:通过用喹啉和吲哚部分代替ISOCA-4的3,4,5-三甲苯甲酰苯基和异维蛋白,设计和合成了一系列新的异孢菌蛋白A-4(ISOCA-4)类似物。这些合成的喹啉吲哚衍生物的结构活性关系(SARS)已经集中研究。两种化合物27c和34b对五种癌细胞系具有最有效的活性,IC 50值范围为2至11nm,其与组合A-4(CA-4,1)相当。进一步的机制研究表明,34b通过与微管蛋白的色素位点结合而有效地抑制微管聚合。进一步的细胞机制研究阐明了34b中断的细胞微管网络,在G2 / M相,诱导的凋亡和K562细胞的凋亡和去极性线粒体中被阻止了细胞周期。此外,34B在伤口愈合和管形成测定中显示出有效的抗血管活性。重要的是,27C和34B在没有表观毒性的情况下显着抑制H22异种移植模型中的肿瘤生长,表明27C和34B应该得到进一步的研究作为癌症治疗的有效抗肿瘤剂。 (c)2018年Elsevier Masson SAS。版权所有。

著录项

  • 来源
  • 作者单位

    China Pharmaceut Univ State Key Lab Nat Med 24 Tong Jia Xiang Nanjing 210009 Jiangsu Peoples R;

    China Pharmaceut Univ State Key Lab Nat Med 24 Tong Jia Xiang Nanjing 210009 Jiangsu Peoples R;

    China Pharmaceut Univ State Key Lab Nat Med 24 Tong Jia Xiang Nanjing 210009 Jiangsu Peoples R;

    China Pharmaceut Univ State Key Lab Nat Med 24 Tong Jia Xiang Nanjing 210009 Jiangsu Peoples R;

    Yantai Univ Sch Pharm Key Lab Mol Pharmacol &

    Drug Evaluat Yantai 264005 Peoples R China;

    China Pharmaceut Univ State Key Lab Nat Med 24 Tong Jia Xiang Nanjing 210009 Jiangsu Peoples R;

    Hong Kong Polytech Univ Dept Appl Biol &

    Chem Technol State Key Lab Chem Biol &

    Drug Discovery;

    China Pharmaceut Univ State Key Lab Nat Med 24 Tong Jia Xiang Nanjing 210009 Jiangsu Peoples R;

    Univ Nottingham Sch Pharm Div Mol Therapeut &

    Formulat Univ Pk Campus Nottingham NG7 2RD;

    China Pharmaceut Univ State Key Lab Nat Med 24 Tong Jia Xiang Nanjing 210009 Jiangsu Peoples R;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

    Quinoline; Indole; Microtubule; Tubulin inhibitor; Colchicine binding site; Antitumor;

    机译:喹啉;吲哚;微管;小管蛋白抑制剂;血氯氨酸结合位点;抗肿瘤;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号